New drug trial targets silent liver disease
NCT ID NCT04006145
Summary
This study tested whether a drug called elobixibat could help adults with fatty liver disease (NAFLD or NASH). Forty-seven participants were randomly assigned to receive either the drug or a placebo for 16 weeks. Researchers measured changes in liver fat, cholesterol levels, and safety to see if the treatment was effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Guardian Angel Research Center, Inc.
Tampa, Florida, 33614, United States
-
Hope Clinical Research
Canoga Park, California, 91303, United States
-
Inland Empire Clinical Trials, LLC
Rialto, California, 92377, United States
-
Integrity Clinical Research, LLC
Doral, Florida, 33166, United States
-
Mercy Medical Center
Baltimore, Maryland, 21202, United States
-
Nature Coast Clinical Research
Inverness, Florida, 34452, United States
-
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.